|
Volumn 336, Issue 6086, 2012, Pages 1253-1255
|
Is it time for a metagenomic basis of therapeutics?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTIINFECTIVE AGENT;
DNA TOPOISOMERASE;
IRINOTECAN;
LEVODOPA;
SALAZOSULFAPYRIDINE;
SULFAPYRIDINE;
WARFARIN;
XENOBIOTIC AGENT;
DRUG;
DRUG DEVELOPMENT;
METABOLISM;
MICROBIAL ACTIVITY;
MICROBIAL COMMUNITY;
ABSORPTION;
ANTIBIOTIC THERAPY;
ANTIMICROBIAL ACTIVITY;
ATHEROSCLEROSIS;
BLOOD BRAIN BARRIER;
CELL SELECTION;
CLINICAL TRIAL (TOPIC);
CLOSTRIDIUM DIFFICILE INFECTION;
DECARBOXYLATION;
DIARRHEA;
DRUG BIOAVAILABILITY;
DRUG EFFICACY;
DRUG METABOLISM;
EGGERTHELLA LENTA;
ENTERITIS;
GASTROINTESTINAL TRACT;
GENETIC MARKER;
HUMAN;
INFECTION;
INTESTINE FLORA;
METAGENOMICS;
MICROBIAL COMMUNITY;
MICROFLORA;
NONHUMAN;
PARKINSON DISEASE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
RISK FACTOR;
SHORT SURVEY;
UNSPECIFIED SIDE EFFECT;
XENOBIOTIC METABOLISM;
|
EID: 84861964370
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.1224396 Document Type: Short Survey |
Times cited : (106)
|
References (14)
|